280 completed, 37 unknown, 29 terminated, 21 recruiting. 115 Phase 3, 115 Phase 4, 62 Phase 2, 51 Not applicable, 43 Phase 1.
Follow Olanzapine: new trials by email Literature Review of Olanzapine trials Research Report on Olanzapine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors Fosrolapitant and Palonosetron; Dexamethasone; Olanzapine, Fosrolapitant and Palonosetron; Dexamethasone - Solid Tumor Cancer | Phase 2 | Active not recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 60 | 2026-09-14 | 2026-09-25 |
| GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer Neoadjuvant chemotherapy, Olanzapine - Gastric Adenocarcinoma, Gastric Cancer | Phase 2 | Not yet recruiting | University of Illinois at Chicago | 26 | 2026-09-01 | 2026-08-21 |
| A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy Netupitant/Palonosetron Hydrochloride, Ondansetron (Control), Aprepitant - Germ Cell Cancer | Early Phase 1 | Not yet recruiting | Ottawa Hospital Research Institute | 10 | 2026-08-01 | 2026-06-23 |
| Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors Pantoprazole, olanzapine, Dexamethasone - Olanzapine, Breast Cancer | Not applicable | Recruiting | Alexandria University | 90 | 2026-05-10 | 2026-08-04 |
| A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron Rolapitant Palonosetron, Dexamethasone, Olanzapine - Lung Cancer | Not applicable | Not yet recruiting | Henan Cancer Hospital | 238 | 2026-04-30 | 2026-03-02 |
| Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications Roluperidone, risperidone, aripiprazole - Negative Symptoms of Schizophrenia | Phase 3 | Recruiting | Minerva Neurosciences | 380 | 2026-04-23 | 2026-07-28 |
| An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC Fosrolapitant and Palonosetron Hydrochloride for Injection, Dexamethasone, Olanzapine - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Recruiting | Shanghai 6th People's Hospital | 200 | 2026-03-10 | 2026-04-30 |
| Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting Olanzapine, Metoclopramide - Nausea, Vomiting | Phase 3 | Recruiting | Affiliated Hospital of Qinghai University | 222 | 2026-02-03 | 2026-04-27 |
| Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis Olanzapine (dose comparison: 2.5 mg, 5 mg, 10 mg) - Solid Tumours, Olanzapine | Completed | Shandong Cancer Hospital and Institute | 2493 | 2026-01-18 | 2026-09-09 | |
| Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial Best Practice, Olanzapine, Questionnaire Administration - Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 66 | 2025-12-24 | 2026-08-18 |
| Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen Fosaprepitant, Tropisetron, Olanzapine - Multiple Myeloma | Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | 92 | 2025-10-31 | 2026-02-17 |
| A Study of Olanzapine in Participants With Bipolar Disorder. Olanzapine - Bipolar Disorder | Recruiting | Boryung Pharmaceutical Co., Ltd | 3000 | 2025-10-30 | 2025-12-04 | |
| Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy Olanzapine Tablets, Placebo - Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer | Phase 3 | Not yet recruiting | Shanghai Children's Medical Center | 100 | 2025-07-01 | 2025-06-25 |
| Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder | Phase 4 | Active not recruiting | Dr. Stavroula Rakitzi | 84 | 2025-06-04 | 2026-05-01 |
| Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy OLANZapine 2.5 MG - Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome | Phase 3 | Recruiting | Blokhin's Russian Cancer Research Center | 100 | 2025-03-28 | 2026-06-08 |
| Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy olanzapine, Placebo - Chemotherapy Induced Nausea and Vomiting | Phase 3 | Recruiting | Mahidol University | 140 | 2025-01-10 | 2025-02-27 |
| A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia Olanzapine-samidorphan；, Olanzapine - Schizophrenia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 654 | 2024-11-01 | 2024-10-21 |
| Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan Olanzapine - Multiple Myeloma, Autologous Stem Cell Transplantation | Phase 3 | Recruiting | Augusta University | 172 | 2024-09-17 | 2024-11-22 |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer Olanzapine, Placebo Administration, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 66 | 2024-07-17 | 2026-07-16 |
| Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC Olanzapine, Nivolumab - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Second Affiliated Hospital of Nanchang University | 156 | 2024-07-02 | 2026-05-05 |
Showing 20 of 396. Sign in to see all of them.
Schizophrenia (174) · Psychotic Disorders (62) · Bipolar Disorder (47) · Vomiting (32) · Nausea (21) · Diabetes Mellitus (11) · Insulin Resistance (11) · Neoplasms (9) · Psychomotor Agitation (9) · Anorexia Nervosa (8) · Depression (8) · Weight Gain (8) · Mental Disorders (7) · Metabolic Syndrome (7) · Dementia (6)
Eli Lilly and Company (38) · Organon and Co (15) · Alkermes, Inc. (9) · H. Lundbeck A/S (6) · Northwell Health (6) · Washington University School of Medicine (6) · National Institute of Mental Health (NIMH) (5) · New York State Psychiatric Institute (5) · Otsuka Pharmaceutical Development & Commercialization, Inc. (5) · Augusta University (4) · Centre for Addiction and Mental Health (4) · Denovo Biopharma LLC (4) · Dr. Reddy's Laboratories Limited (4) · Janssen Research & Development, LLC (4) · Teva Branded Pharmaceutical Products R&D LLC (4)
United States (179) · China (42) · Canada (33) · Germany (25) · Russia (22) · Spain (17) · India (14) · France (13) · Brazil (12) · Puerto Rico (12) · Taiwan (11) · Argentina (10) · Mexico (10) · Romania (10) · Bulgaria (9)
David McDonnell, MD (4) · Evelyn Attia, MD (3) · John W Newcomer, MD (3) · Thomas S Clark, M.D. (3)
PMID 38958149, PMID 21095016, PMID 22198451, PMID 22967772, PMID 19210948, PMID 20840778, PMID 15367925, PMID 17375138, PMID 20537128, PMID 20537130, PMID 21586165, PMID 22935168, PMID 23290326, PMID 23473546, PMID 24329543, PMID 24417745, PMID 24423017, PMID 25890643, PMID 29105003, PMID 32931400, PMID 36375174, PMID 37756123, PMID 10332540, PMID 10849191, PMID 11030465, PMID 11383973, PMID 12736106, PMID 14645311, PMID 16172203, PMID 16585434, PMID 16585435, PMID 16754835, PMID 16818861, PMID 16829550, PMID 17006758, PMID 17035647, PMID 17151158, PMID 17151159, PMID 17159456, PMID 17335316, PMID 17335320, PMID 17459549, PMID 17606657, PMID 17606658, PMID 17667476, PMID 17667477, PMID 17851042, PMID 17898346, PMID 17898351, PMID 17984395
2009 (3), N01MH090001 (3), N01MH90001 (3), 2008 (2), R21MH069868 (2), UG1CA189823 (2), 2014 (1), 2019 (1), 2023 (1), K08MH001765 (1), K23MH074540 (1), M01RR000036 (1), P01HD026927 (1), P30CA015083 (1), P30CA069533 (1)